GBA Presents: RADIO SAVANT-!

Van-! ASAN lets do this together we either go to the moon or we blow up together e plurbus uniium@!!!!

ASANA INC CL A selected

Last Price by Size over ExchangeLast Price x Size / Exch
Last price:
18.09
Size and net change:
x200shares,Dup+0.6100up(+3.49%)
Bid x size
Bid price by size
18.09xby300sharesN
Ask x size
Ask price by size
18.10xby1400sharesZ
Volume
Volume
4.00Million
Order preview details
Action Quantity Description Price type Price Duration
Buy 375 ASANA INC CL A (ASAN) Market MKTMarket Good for Day
Estimated commission
$0.00
Estimated total cost
$6,787.50<--------------- Roll the dice! F You X-ray company!!!!!!!
 
Stoney I bought back some UNCY in pre-market and up to $1.45 after selling most at $1.90s yesterday. After telling Ken about it at $1.89-.90 it hit $2.15 and tanked.

ASUR $17.5 Mays had action today, new monthly. Razor stock, like RELL and AEHR(<$7 long ago.).
 
You woke me up for ASAN, chart is gorgeous! You are silly Stoney! Remember the Founder was buying from $60-$80s? I’ve been lugging Potbelly since you mentioned it, what do I do? How about that ASUR?



YOU MEAN PORTELLOS I HOPE.! //

YES YES I MENTIONED THE SHADY DOINGS OF THE CEO INSIDER BUYING.... WE STARWETD TRACKING THIS A FEW DAYS AGO.. I FORGET WHY- I SHOULD PROBABLY RE CHECK.
 
Stoney I bought back some UNCY in pre-market and up to $1.45 after selling most at $1.90s yesterday. After telling Ken about it at $1.89-.90 it hit $2.15 and tanked.

ASUR $17.5 Mays had action today, new monthly. Razor stock, like RELL and AEHR(<$7 long ago.).


MY FEELING IS ASUR DID NOTHING WRONG. HOLD.

Markets will do what they do but I looked at the earn report and it's good.

And you kind of catch this co in a good place with recurring rev.

Asure Software price target raised to $20 from $14 at Needham 02/28 ASUR Needham analyst Ryan MacDonald raised the firm's price target on Asure Software to $20 from $14 and keeps a Buy rating on the shares. The company saw a recurring revenue beat of 9.2%, which is "well above" typical results, the analyst tells investors in a research note. The firm adds that investors will view positively the updated guidance for FY23, which is 6% higher than the previous guide and is driven by strength in recurring revenue not professional services.
 
Regarding UNCY I don't know the company but read that mon PR carefully--

Unicycive Therapeutics announced that the company has signed a securities purchase agreement with certain healthcare-focused institutional investors that will provide up to $130M in gross proceeds to Unicycive through a private placement that includes initial upfront funding of $30M

That $130 mln is really $30 mil. This I would boot.
 
The world is so scary. There is a list of worries for the market. A wall of worries.

Asana options imply 15.0% move in share price post-earnings 13:34 ASAN Pre-earnings options… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial Show Related Items >>
 
Back
Top